A Study in Patients With Advanced or Metastatic Cancer

Status Completed

Clinical Trial Summary

Study JWAA is a multicenter, nonrandomized, open-label, dose-escalation Phase 1 study of oral LY2780301 in patients with advanced solid tumors.

Clinical Trial Description

JWAA will consist of the following treatment phases parts:

Part A - Dose escalation phase using a once-daily dosing schedule. Part B - Dose escalation phase using a twice-daily dosing schedule. Part C - Dose expansion phase using the maximum tolerated dose from either Part A or Part B. ;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01115751
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 1
Start date	March 2010
Completion date	July 2012

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00065117` - Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.	Phase 2
Completed	`NCT00039780` - Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel	Phase 3
Terminated	`NCT00048893` - Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer	Phase 1/Phase 2
Completed	`NCT00037869` - High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors	Phase 3
Completed	`NCT02265549` - Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases	N/A
Completed	`NCT00034918` - This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer	Phase 2
Terminated	`NCT01115803` - A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors	Phase 1
Completed	`NCT00056173` - Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma	Phase 1/Phase 2
Recruiting	`NCT05419518` - Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas	Phase 2
Terminated	`NCT00034697` - Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)	Phase 2
Completed	`NCT00055471` - A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer	Phase 2
Completed	`NCT00046514` - ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer	Phase 2
Completed	`NCT00046527` - Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer	Phase 3
Completed	`NCT00041808` - Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver	Phase 1/Phase 2
Completed	`NCT00037609` - Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients	Phase 1/Phase 2
Withdrawn	`NCT00038038` - Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole	N/A
Completed	`NCT03670992` - Surgical Treatment of Pancreatic RCC Metastases
Terminated	`NCT00050336` - Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)	Phase 3
Recruiting	`NCT03563326` - Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART)	Phase 1
Completed	`NCT00044863` - Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma	Phase 2